Protagen AG, of Dortmund, Germany, started a collaboration with the University of California, San Francisco, to utilize Protagen's Serotag technology to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors and therapeutic vaccines. Terms were not disclosed.